Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia

Medical Science Monitor

Volumn 10, Issue 4, 2004, Pages

  Skorokhod, Oleksil A ^a   Garmaeva, Tat'yana Ts ^a   Vitvitsky, Victor M ^a   Isaev, Valentin G ^a   Parovichnikova, Elena N ^a   Savchenko, Valerii G ^a   Ataullakhanov, Fazoil I ^a  

^a NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

Author keywords

Acute leukemia; Carrier erythrocytes; Daunorubicin; Pharmacokinetics

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; DAUNORUBICIN; RUBOMYCIN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CELL SUSPENSION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG TOLERABILITY; ERYTHROCYTE; ERYTHROCYTE ADHESIVENESS; ERYTHROCYTE DEFORMABILITY; FEMALE; HOMEOSTASIS; HUMAN; MALE; SIDE EFFECT;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; DAUNORUBICIN; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTES; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED;

EID: 1942534729     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Wiernik PH, Banks PL, Case DC Jr et al: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood, 1992; 79: 313-19
2. Savchenko VG, Parovichnikova EN, Isaev VG et al: The treatment of acute lymphoblastic leukemias in adults. Ter Arkh, 1997; 69: 5-11
3. Lefrak EA, Pitha J, Rosenheim S, Gottleib JA: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 1973; 32: 302-14
4. Kovcin V: Disturbed cardiac rhythm as a manifestation of cardiotoxicity of individual doses of anthracycline cytostatics. Med Sci Monit, 1999; 5: 32-39
5. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K: Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of the literature. Med Sci Monit, 2000; 6: 411-20
6. Rachman A, Fumagalli A, Barbieri B et al: Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Chemother Pharmacol, 1986; 16: 22-27
7. Seymour LW, Ulbrich K, Strohalm J et al: The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol, 1990; 39: 1125-31
8. Dillman RO, Johnson DE, Shawler DL, Koziol JA: Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res, 1988; 48: 6097-102
9. Lutsenko SV, Feldman NB, Finakova GV et al: Antitumor activity of alpha fetoprotein and epidermal growth factor conjugates in vitro and in vivo. Tumor Biol, 2000; 21: 367-74
10. Feldman NB, Kiselev SM, Gukasova NV et al: Antitumor activity of α-fetoprotein conjugate with doxorubicin in vitro and in vivo. Biochemistry (Moscow), 2000; 65: 967-71
11. Gabizon AA: Liposomal anthracyclines. Hematol Oncol Clin North Am, 1994; 8: 431-50
12. Coukell AJ, Spencer CM: Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs, 1997; 53: 520-38
13. Tseng YL, Hong RL, Tao MH, Chang FH: Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer, 1999; 80: 723-30
14. Pea F, Russo D, Michieli M et al: Liposomal daunorubicin plasmatic and renal diposition in patients with acute leukemia. Cancer Chemother Pharmacol, 2000; 46: 279-86
15. Schrijvers D, Highley M, De Bruyn E et al: Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs, 1999; 10: 147-53
16. Loos WJ, Verweij J, Gelderblom HJ et al: Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans. Anticancer Drugs, 1999; 10: 705-10
17. Momerency G, Van Cauwenberghe K, Highley MS et al: Partitioning of ifosfamide and its metabolites between red blood cells and plasma. J Pharm Sci, 1996; 85: 262-65
18. Ihler GM: Erythrocyte carriers. Pharmac Ther, 1983; 20: 151-69
19. Lewis DA, Alpar HO: Therapeutic possibilities of drugs encapsulated in erythrocytes. Int J Pharm, 1985; 22: 137-46
20. Ataullakhanov FI, Vitvitsky VM, Kovaleva VL, Mironova B: Rubomicin loaded erythrocytes in the treatment of mouse tumor P388. Adv Exp Med Biol, 1992; 326: 209-13
21. Ataullakhanov FI, Kulikova EV, Vitvitsky VM: Doxorubicin binding by human erythrocytes. Adv Biosci, 1994; 92: 163-68
22. Zocchi E, Tonetti M, Polvani C et al: Encapsulation of doxorubicin in liver-targeted erythrocytes increases the therapeutic index of the drug in a murine metastatic model. Proc Natl Acad Sci USA, 1989; 86: 2040-44
23. Benatti U, Zocchi E, Tonetti M et al: Enhanced antitumor activity of adriamycin by encapsulation in mouse erythrocytes targeted to liver and lungs. Pharmacol Res, 1989; 21: 27-33
24. Ataullakhanov FI, Balasheva TV, Bukhman VM et al: Treatment of Rausher virus induced murine erythroblastic leukemia with rubomycin loaded erythrocytes. Adv Biosci, 1994; 92: 177-83
25. Gaudreault RC, Bellemare B, Lacroix J: Erythrocyte membrane-bound daunorubicin as a delivery system in anticancer treatment. Anticancer Res, 1989; 9: 1201-5
26. Kitao T, Hattori K, Takeshita M: Agglutination of leukemic cells and daunomycin entrapped erythrocytes with lectin in vitro and in vivo. Experientia, 1978; 34: 94-95
27. Matherne CM, Satterfield VC, Gasparini A et al: Clinical efficacy and toxicity of doxorubicin encapsulated in glutataldehyde treated erythrocytes administered to dogs with lymphosarcoma. Am J Vet Res, 1994; 55: 847-53
28. Tonetti M, Zocchi E, Guida L et al: Use of glutaraldehyde treated amologous human erythrocytes for hepatic targeting of doxorubicin. Adv Exp Med Biol, 1992; 326: 307-17
29. Ataullakhanov FI, Kulikova EV, Vitvitsky VM: Reversible binding of anthracycline antibiotics to erythrocytes treated with glutaraldehyde. Biotechnol Appl Biochem, 1996; 24: 241-44
30. Ataullakhanov FI, Isaev VG, Kohno AV et al: Pharmacokinetics of doxorubicin in patients with lymphoproliferative disorders after infusion of doxorubicin-loaded erythrocytes. In Erythrocytes as Drug Carriers in Medicine (eds. Sprandel U. and Way JL.) New York, London: Plenum Press; 1997, p. 137-42
31. Skorokhod AA, Vitvitsky VM, Kuhlmann RA, Ataullakhanov FI: Detrimental effects of daunorubicin and doxorubicin on human erythrocytes, an in vitro study. Vopr Oncol, 1999; 4: 374-79
32. Lisovskaia IL, Ataullakhanov FI, Tuzhilova EG, Vitvitsky VM: Analysis of geometric parameters and mechanical properties of erythrocytes by filtration through nuclear membrane filters. II. Experimental verification of a mathematical model. Biofizika, 1994; 39: 864-71
33. Finkel JM, Knapp KT, Mulligan LT: Fluorometric determination of serum levels and urinary excretion of daunomycin (NSC-82151) in mice and rats. Cancer Chemother Rep, 1969; 53(3): 159-64
34. De Flora A, Benatti U, Guida L, Zocchi E: Encapsulation of adriamycin in human erythrocytes. Proc Natl Acad Sci USA, 1986; 83: 7029-33
35. Karukstis KK, Thompson EHZ, Whiles JA, Rosenfeld RJ: Deciphering the fluorescence signature of daunomycin and doxorubicin. Biophys Chem, 1998; 73: 249-63
36. Sadzuka Y, Hirota S: Does the amount of an antitumor agent entrapped in liposomes influence its tissue distribution and cell uptake? Cancer Lett, 1998; 131: 163-70
37. Alberts DS, Bachur NR, Holtzman JL: The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther, 1971; 12: 96-104
38. Paul C, Baurain R, Gahrton G, Peterson C: Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia. Cancer Lett, 1980; 9: 263-69
39. Speth PA, Linssen PC, Pauw BE, Witte TJ: Cellular pharmacokinetics of daunomycin administered as continuous intravenous infusion in the treatment of acute non-lymphocytic leukaemia. Br J Haematol, 1986; 63: 602-5
40. Robert J, Gianni L: Pharmacokinetics and metabolism of anthracyclines. Cancer Surv, 1993; 17: 219-52
41. Preisler HD, Gessner T, Azarnia N et al: Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol, 1984; 12: 125-30
42. Robert J, Illiadis A, Hoerni B et al: Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic and clinical short-term response. Eur J Cancer Clin Oncol, 1982; 18: 739-45
43. Frost B-M, Eksborg S, Bjork O et al: Pharmacokinetics of doxorubicin in children with acute limphoblastic leukemia: Multi-institutional collaborative study. Med Pediatr Oncol, 2002; 38: 329-37
44. Danesi R, Fogli S, Gennari A et al: Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet, 2002; 41: 431-44